Clinical Trial Update: Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients with Previously Untreated Chronic Lymphocytic Leukaemia (CLL) [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial compares three treatment strategies in previously untreated chronic lymphocytic leukemia: ibrutinib monotherapy, fixed-duration venetoc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Ibrutinib (ibrutinib)
• Obinutuzumab (obinutuzumab)
• Venetoclax (venetoclax)

Snippet

Sponsor: German CLL Study Group | Conditions: Chronic Lymphoid Leukemia | Phase 3 | Status: ACTIVE_NOT_RECRUITING